免疫吸附治疗强直性脊柱炎疗效观察

王凯; 李鞠; 李慧; 孟德钎

doi:10.3969/j.issn.1671-4091.2019.08.009

中国血液净化 >

2019 , Vol. 18 >Issue 08: 547 - 549

DOI: https://doi.org/10.3969/j.issn.1671-4091.2019.08.009

临床研究

免疫吸附治疗强直性脊柱炎疗效观察

王凯 ,
李鞠 ,
李慧 ,
孟德钎

展开

1. 南京医科大学附属淮安一院风湿免疫科

收稿日期: 2018-06-28

修回日期: 2019-05-06

网络出版日期: 2019-08-15

收起

The efficacy of immunoabsorption therapy for ankylosing spondylitis

WANG Kai ,
LI Ju ,
LI Hui ,
MENG De-Qian

Expand

1Department of Rheumatology, Huai’an First People’s Hospital, Nanjing Medical University,Huai’an 223001, China

Received date: 2018-06-28

Revised date: 2019-05-06

Online published: 2019-08-15

Fold

摘要

【摘要】目的观察免疫吸附治疗强直性脊柱炎(ankylosing spondylitis,AS)的疗效。方法选取AS 常规治疗组30 例和AS 免疫吸附治疗组30 例为实验对象，分别于治疗前、治疗后1 周、1 月、3 月后检测3组红细胞沉降率(erythrocyte sedimentation rate,ESR)、C 反应蛋白(C-reaction protein,CRP)，并评估Bath AS 疾病活动指数评分(Bath AS disease activity index,BASDAI)。结果①免疫吸附治疗1 周治疗组患者较对照组ESR、CRP、BASDAI 的差异有统计学意义(Z 值分别为2.692,2.511,3.866；P值分别为-0.007，0.012，＜0.001)。②免疫吸附治疗3 月后免疫吸附治疗组较对照组ESR、CRP 下降，BASDAI评分降低，差异有统计学意义(Z 值分别为2.905, 6.427, 2.000；P 值分别为0.004,＜0.001,0.045)；③治疗3 月后免疫吸附治疗组较对照组非甾体类抗炎药的用量下降，差异有统计学意义(Z =4.296,P＜0.001)。结论免疫吸附治疗AS，炎症指标恢复快，起效快，病情易于稳定。免疫吸附治疗可减轻炎症反应。

关键词： 强直性脊柱炎; 免疫吸附

本文引用格式

王凯 , 李鞠 , 李慧 , 孟德钎 . 免疫吸附治疗强直性脊柱炎疗效观察[J]. 中国血液净化, 2019 , 18(08) : 547 -549 . DOI: 10.3969/j.issn.1671-4091.2019.08.009

Abstract

【Abstract】Objective To investigate the efficacy of immunoadsorption therapy for ankylosing spondylitis (AS). Methods A total of 60 patients with AS were recruited and allocated into control group (n=30) or immunoadsorption group (n=30). Erythrocyte sedimentation rate (ESR), C- reaction protein (CRP) and the score of Bath AS disease activity index (BASDAI) were assessed before the treatment and at the first week, first month and 3rd month after the treatment. Results At the first week after the treatment, ESR (Z=2.692,P=-0.007), CRP (Z=2.511, P=0.012) and BASDAI score (Z=3.866, P=0.000) were significantly lower in immunoadsorption group than in control group. At the 3rd month after the treatment, ESR (Z=2.905, P=0.004), CRP (Z= 6.427, P=0.000) and BASDAI score (Z=2.000, P=0.045) were still lower in immunoadsorption group than in control group; in addition, the doses of non-steroid anti-inflammatory drugs (NSAIDs) reduced in immunoadsorption group as compared with those in control group (Z=4.296, P=0.000). Conclusion Immunoadsorption treatment for AS has the advantages of fast improvement of inflammatory biomarkers and clinical conditions with stable efficacies. Immunoadsorption therapy can also alleviate the inflammation responses in AS patients.

Key words： Ankylosing spondylitis; Immunoadsorption

参考文献

参考文献
[1] Dougados M, Baeten D. Spondyloarthritis[J]. The Lancet, 2011,377(9783):2127-2137.
[2] 中华医学会风湿病学分会. 强直性脊柱炎诊断及治疗指南[J]. 中华风湿病学杂志, 2010,14(8):557-559.
[3] Baraliakos X, Heldmann F, Callhoff J, et al. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography[J]. Annals of the rheumatic diseases, 2013:2013-203425.
[4] Haroon N, Inman R D, Learch T J, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis[J]. Arthritis & Rheumatology, 2013,65(10):2645-2654.
[5] Poddubnyy D, Sieper J. Radiographic progression in ankylosing spondylitis/axial spondyloarthritis: how fast and how clinically meaningful?[J]. Current opinion in rheumatology, 2012,24(4):363-369.
[6] 张雪珍, 庄宇, 刘滢. DNA免疫吸附疗法治疗狼疮间质性肺炎的近期疗效及安全性分析[J]. 广西医科大学学报, 2018(1):61-64.
[7] 曹丽娜, 殷寒秋, 李朝虹, 等. 甲泼尼龙和环磷酰胺冲击联合免疫吸附治疗多发性肌炎和皮肌炎疗效的随机对照研究[J]. 临床药物治疗杂志, 2018,16(3):46-49.
[8] 熊礼佳, 叶琨, 刘园园, 等. 免疫吸附治疗对自身免疫性疾病的疗效及安全性探讨[J]. 中国临床新医学, 2017,10(1):1-4.
[9] 赵龙姝, 辛婕琛, 孙丽华, 等. 免疫吸附治疗难治性类风湿关节炎的临床应用[J]. 中国血液净化, 2017,16(10):681-683.
[10] Du Clos T W, Mold C. C-reactive protein[J]. Immunologic research, 2004,30(3):261-277.

Options

文章导航

模态框（Modal）标题

摘要

本文引用格式

Abstract

参考文献